28 August 2026
CTX310 one-year lipid cuts reported from Phase 1a
A single intravenous infusion of CTX310 at the highest dose produced mean reductions from baseline of 79% for ANGPTL3, 48% for triglycerides, and 53% for low-density lipoprotein at one year.
The full briefing is in the app.